Rituxan

Rituximab (Rituxan) Two 1000-mg infusions separated by 2 weeks IV infusion 4 weeks IR Monitor for infection ... [Pg.873]

Rituximab (Rituxan ) Rituximab is a chimeric monoclonal antibody directed against the CD20 molecule on B lymphocytes.21 Similar to other B-cell malignancies, CLL... [Pg.1419]

Rituxan) hypotension with or without a steroid to alleviate infusion-related reactions. Rate of infusion should be increased gradually to minimize reactions. [Pg.1420]

Rituxan Rituximab Genentech Treatment of relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkins lymphoma... [Pg.695]

Rituxan (anti-CD20 monoclonal antibody) Liquid for IV injection Store at 2-8°C protect from light lOOmg or 500mg vial 9.0mg/mL NaCl, 7.35mg/mL Na-citrate, 0.7 mg/mL polysorbate 80... [Pg.709]

Genentech was founded in 1976 by scientist Herbert Boyer and the venture capitalist Robert Swanson. Headquartered in San Francisco, it employs almost 5000 staff worldwide and has 10 protein-based products on the market. These include hGHs (Nutropin, Chapter 11), the anti-body-based products Herceptin and Rituxan (Chapter 13) and the thrombolytic agents Ac-tivase and TNKase (Chapter 12). The company also has 20 or so products in clinical trials. In 2004, it generated some US 4.6 billion in revenues. [Pg.7]

Rituxan (Genentech) Monoclonal antibody based (non-Hodgkin s lymphoma) 1.5... [Pg.8]

Antibodies Avastin, Bexxar, Erbitux, Herceptin, Humaspect, Humira, Mabcampath/Campath-Hl, Mabthera/ Rituxan, Mylotarg, Neutrospec, Oncoscint, Orthoclone OKT-3, Prostascint, Raptiva, Remicade, Simulect, Synagis, Xolair, Zenapax, Zevalin... [Pg.32]

Rituxan (Rituximab chimaeric Mab directed against CD20 antigen found on the surface of B-lymphocytes)... [Pg.380]

Mabthera (Rituximab, chimaeric Mab directed against CD 20 surface antigen of B-lymphocytes) Hoffmann La Roche (see also Rituxan) Non-Hodgkin s lymphoma... [Pg.381]

Rituximab (Rituxan ) is a chimeric IgGl anti-CD20 mAb that selectively targets B lymphocytes. CD20 is a transmembrane phosphoprotein that is densely expressed on... [Pg.134]

Starting Down the Path to Rituxan High-Level Expression... [Pg.565]

The Surprising Effects of Human B-Cell Depletion Rituxan Usage... [Pg.565]

The first two antibodies our group tried to express in this vector system within mammalian cells had mistakes in the genetic material that coded for variable regions and, consequently, did not express any antibody at all. The first antibody that was produced by recombinant technology at IDEC using this vector system was in early 1991. It was supposed to be a chimeric anti-CD4 antibody, but the antibody secreted by the cells did not bind to CD4. CD4 is a surface molecule on the leukocytes known as T cells. A primatized antibody (a chimeric antibody where the variable domains are isolated from a cynomol-gus monkey see Figure 32.2) to CD4 was produced later that year. That antibody ended up in clinical trials in humans at the same time as Rituxan. [Pg.570]

The time between immxmizing the mice with CD20 (August 1990) and filing the IND for Rituxan (December 1992) was 2 years and 4 months. That brief span encompassed the first time IDEC had ever produced and manufactured a recombinant antibody in CHO cells for clinical trials in humans. The IND also included safety and efficacy data in primates, in which monkeys who had had their normal B cells completely depleted from their blood and depleted in part from their lymph nodes showed no adverse events. In addition, a human y4 version of rituximab was shown not to deplete B cells in monkeys, indicating for the first time that the Fc portion of the human yl antibody was contributing to depletion of cells with CD20 on their surface in vivo ... [Pg.576]

In addihon to treahng tumors, and because depleting B cells in humans with rituximab has been found to be safe, Rituxan is now in clinical trials and has shown efficacy for a number of autoimmune disorders. These include rheumatoid arthritis, idiopathic thrombocytopenia purpura (ITP, a platelet-depletion disorder), and lupus. It is expected that depleting B cells with rituximab will be approved in a nononcology indication within several years. [Pg.579]

Rituxan Rituximab IDEC (now Biogen Idee), Gambridge, MA Anti-CD20 Non-Hodgkin s lymphoma 1997... [Pg.580]

See also in sourсe #XX -- [ Pg.7 , Pg.8 ]

See also in sourсe #XX -- [ Pg.416 , Pg.505 ]

See also in sourсe #XX -- [ Pg.302 , Pg.303 ]

See also in sourсe #XX -- [ Pg.578 ]

See also in sourсe #XX -- [ Pg.218 ]

See also in sourсe #XX -- [ Pg.419 ]

See also in sourсe #XX -- [ Pg.9 , Pg.10 ]

See also in sourсe #XX -- [ Pg.5 , Pg.5 , Pg.228 , Pg.230 ]

See also in sourсe #XX -- [ Pg.364 ]

See also in sourсe #XX -- [ Pg.157 ]

See also in sourсe #XX -- [ Pg.50 ]

See also in sourсe #XX -- [ Pg.10 ]

See also in sourсe #XX -- [ Pg.440 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...